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188 Elongation of the small intestine (without histological changes)
in young pigs with experimentally induced exocrine pancreatic
insufﬁciency (EPI) − used as a model for children with EPI
A. Mo¨ßeler1, T. Schwarzmaier1, P.C. Gregory2, J. Kamphues3. 1University
of Veterinary Medicine, Hannover, Institute for Animal Nutrition, Hannover,
Germany; 2Abbott Laboratories (GmbH), Hannover, Germany; 3University of
Veterinary Medicine, Hannover, Hannover, Germany
Objectives: Increase of tissue mass of the gastro intestinal tract (GIT) and length
of the small intestine (smi) was found in pigs with experimentally induced EPI
before. This study aimed to look more detailed at the assumed mechanisms behind
these ﬁndings.
Methods: In 8 pigs aged 8 weeks the pancreatic duct was ligated (PL), another
4 pigs were sham operated and served as controls (C). 3 weeks post OP the PL-
pigs were split into 2 groups (each n = 4): PL+E: supplied with Creon® (~6300
Ph.Eur.E lipase/g fat) and PL+0: no enzyme substitution. Animals were pair fed
until week 8 post OP, then fed ad libitum. In week 11 post OP pigs were euthanized.
Results: EPI resulted in a signiﬁcantly reduced prececal (prc.) digestibility of
starch (C: 88.4±1.59a, PL+0: 33.4±15.7c), while enzyme substitution caused a
distinct increase (PL+E: 79.7±3.25b). When excluding the data of one PL+0 pig
(distinctly smallest one) the smi length (m) was signiﬁcantly higher (p< 0.026) in
PL+0 (21.1±1.04a) compared to those of C (17.2±1.76b) and PL+E (18.2±1.33b);
[PL+0 n = 3; PL+E n = 4, C n = 4]. Correlation between body length and smi
length was bad (R2 = 0.001) as well as the correlation between smi length and
empty bw [bw without GIT; R2 = 0.214]. Negative correlation between smi length/
kg empty bw and prc. digestibility of starch (R2 = 0.88) and between the mass of
cecum per kg empty bw and prc. starch digestibility (R2 = 0.933) were quite good.
Conclusion: The elongation of the smi in case of EPI has not been described
before to our knowledge and seems to be a kind of adaptation. Whether reduced
enzymatic digestion or increased bacterial fermentation are the predominant factors
is not clear up to date.
189 The variability of carbohydrate antigen 19-9 (CA 19-9) levels in
cystic ﬁbrosis patients
M. Leichsenring1, B. Rueckel1, P. Meissner1, W. Kratzer1. 1Ulm University, Ulm,
Germany
Objectives: CA19-9 is a marker of gatrointestinal malignancies and known to
be increased in CF-patients. However, only few data exist on the inter- and
intraindividual variability of CA19-9 levels in relation to the clinical status. We
therefore investigated plasma CA19-9 levels in 66 CF-patients at various time
points.
Methods: Blood was taken in the scope of routine clinical investigations. Serum
CA19-9 was determined by ElectroChemiLuminescence Immuno Assay (ECLIA)
using a Roche Immunoassayautomat Cobas 6000. Clinical data were collected
according to standard protocols, as used in German CF centres.
Results: 37/66 (56.1%) CF-patients had normal CA19-9 levels below 32 IU/ml and
14/66 (21.2%) showed levels above 100 IU/ml (overall mean 57.8 IU/ml; 95%CI
38.1–77.5 IU/ml; median 29.8). There was no relation between CA19-9 and gender,
age or PSA status. The intraindividual variability at various time points was
remarkably low. One patient with initially high CA19-9 (799.8 IU/ml) showed a
sharp increase (1,810 IU/ml) within one month, without any clinical or laboratory
sign of pancreatitis, cholestasis or other gastrointestinal pathology. MRI and endo-
sonography revealed multiple cystic formations with dilatated branches in the tail
of the pancreas, as is seen in intraductal papillary mucinous neoplasms (IPMN).
Conclusion: Despite overall increased levels of CA19-9 in CF-patients only few
reveal values above 100 IU/ml. It seems reasonable to follow up these patients
more closely, with monitoring of CA19-9 and extended radiological diagnostics
were required.
190 Pancreatitis in patients with CF
A. Sojo Aguirre1, N. Martinez Ezquerra1, C. Bouson˜o Garcı´a2, M.D. Acun˜a
Quiros3, J. Manzanares Lopez Manzanares4, S. Heredia Gonzalez5, F. Baranda
Garcia1, C. Vazquez Cordero1. 1Hospital Universitario Cruces, Bilbao, Spain;
2Hospital Universitario Central de Asturias, Oviedo, Spain; 3Hospital Universitario
Nin˜o Jesus, Madrid, Spain; 4Hospital Universitario Doce de Octubre, Madrid,
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Patients with cystic ﬁbrosis may develop either single or recurrent bouts of acute
pancreatitis. This complication has been mostly reported in pancreatic-sufﬁcient
teenagers and adults with mild pulmonary disease.
Objective:We describe the progress of a previously reported group of patients with
CF and pancreatitis.
Methods: Multi-centre retrospective study in 5 CF-Centres of all patients with a
diagnosis of CF and pancreatitis.
Results: 36 out of 579 (4.5%) patients with CF had acute pancreatitis at a median
age of 14.2 y. 3 had undiagnosed CF when they presented with pancreatitis.
16 (61.5%) had a single episode and 10 (38.5%) two or more. 6 had triggering
factors. All presented with abdominal pain and most with nausea, vomiting and
malaise. Both lipase and amylase serum concentrations were increased. Abdominal
ultrasounds showed various changes. Pulmonary disease was mild in 69.2% (median
FEV1 84% Pred.). 46% had pancreatic insufﬁciency (PI), 34.6% CF-related liver
disease, 19.2% nasal polyps and 38.5% had complications related salt losses by
the sweat. Most (87.5%) had a satisfactory nutritional condition. 77% carried the
F508del mutation (homozygotes or compound-heterozygotes). No major complica-
tions were reported.
Conclusions: The frequency of pancreatitis was higher (4.5%) than the 2.9% found
in another study and that generally quoted. While the percentage of those with
PI (46%) was lower than we found in an earlier report (57%) it still is higher
than that generally reported. The condition was more frequent in adolescents with
mild pulmonary disease. No any association between clı´nical, demographic and CF
genotype variables and an increased risk of pancreatitis was found.
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Distal intestinal obstruction syndrome (DIOS), a speciﬁc complication of CF has an
accurate deﬁnition based on ESPGHAN CF Working Group (JPGN 2010). This is
the ﬁrst prospective survey on concomitant risk factors and treatment alternatives.
Methods: New cases of DIOS from 2009–2012 were reported through an ECFS
website database and analysed by the coordinating centre located in Paris (data
under process). Ethical approval was obtained in each country.
Results: 102 cases from 10 countries (28 CF centres) were reported; 60% were
males, age was 14.4[6.5–23.5] years and 45% had a complete DIOS. 58% had
either a previous DIOS or a recurrent episode during the study period. Frequency
of meconium ileus, pancreatic insufﬁciency, CF liver disease, proton pomp inhibitor
prescription was respectively 40, 92, 22, 54%; diabetes and chronic Pseudomonas
aeruginosa in adults, 49 and 68%. Considering the 112 DIOS episodes, outdoor
temperature was >20º in 54%, beverage intake was insufﬁcient in 50%, poor
compliance with pancreatic enzymes was uncommon (12%), patients were on a
high ﬁber diet or fat diet in only 2 and 9%. All complete DIOS required IV
hydration, non opioid (85%), or opiod (17%) pain relief, Gastrograﬁn enema (G)or
polyethylene glycol (PEG) lavage in 87%, 4% a colonoscopy and 9% surgery;
around half of the incomplete DIOS received IV hydration, non opioid pain relief
and G enema or PEG. Overall 84% of the patients were prescribed maintenance
therapy.
Conclusion: DIOS is multifactorial but climate and poor compliance do not appear
to be major contributing factors. Despite variation in medical management, surgery
was required in 2 centres only (9% of complete DIOS).
